Sciele Pharma (SCRX) – 7/15/08
LARx (head lice product) NDA
Different mode of action versus current neurotoxic lice killers

Theravance (THRX) – 7/21/08
Telavancin NDA
A good chance for a second approvable letter due to outstanding issues with trial conduct and recent approvable letters for other antibiotics

Warner Chilcott (WCRX) – 7/21/08
Topical alprostadil NDA

Amgen (AMGN) – 7/23/08
Nplate (romiplostim) BLA
Recommended by FDA Oncology Panel (with monitoring of patients)

Medicines Co. (MDCO) – 7/24/08
Angiomax sNDA

Vanda (VNDA)/Titan Pharma (TTP) – 7/27/08
Fanapta (iloperidone) NDA
Read my previous pan of both stocks

CV Therapeutics (CVTX) – 7/27/08
Ranexa (ranolazine) sNDA (3 label expansions)
first-line angina indication should boost sales + recent EU approval for second-line use in chest pain

Noven Pharma (NOVN) – 7/31/08
Stavzor (delayed-release valproic acid) NDA

Last 5 posts by Mike Havrilla

• RxNews Recap: 01-27-10 Repros Therapeutics rockets on news of FDA meeting. GenVec sinks on offering - January 27th, 2010
• Albertis $12.8B Bid to Lease PA Turnpike Expires with No Deal - October 1st, 2008
• Congress Working Overtime: $634B Spending Bill and Bailout Plan - September 27th, 2008
• Pfizer is a Big Pharma Buy - September 24th, 2008
• Bristol-Myers Ups Bid to $62 for ImClone - September 23rd, 2008